ResearcherHarvard UniversityActive in the last 2 years
Michael D. Lanuti
Matched on ORCID iD 0000-0001-6049-1276; OpenAlex author ID A5063691307. Sources: ClinicalTrials.gov.
Their work
- Papers
- 3
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2018: 1 paper · 2019: none · 2020: 1 paper, 1 trial · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 3
- Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Co-author DOI 10.7150/thno.100116↗
- Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Co-author DOI 10.1158/1078-0432.ccr-18-1359↗
- Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Co-author DOI 10.1242/dmm.034793↗
Trials 1
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shadi Abdar Esfahani · 1 shared paper, 1 shared trial, 2020–2024 · strength 0.51
- Peter D. Caravan · 3 shared papers, 2018–2024 · strength 0.30
- Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- Kenneth K. Tanabe · 3 shared papers, 2018–2024 · strength 0.30
- Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- Motaz Qadan · 2 shared papers, 2020–2024 · strength 0.23
- Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Derek J. Erstad · 2 shared papers, 2018–2020 · strength 0.15
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- Cristina R. Ferrone · 2 shared papers, 2018–2020 · strength 0.15
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- Nabeel M. Bardeesy · 2 shared papers, 2018–2020 · strength 0.15
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- Bryan C. Fuchs · 2 shared papers, 2018–2020 · strength 0.15
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- David Tsai Ting · 1 shared paper, 2024 · strength 0.15
- Theodore Sunki Hong · 1 shared paper, 2024 · strength 0.15
- Carlos Fernández-del Castillo · 1 shared paper, 2024 · strength 0.15
- Onofrio A. Catalano · 1 shared paper, 2024 · strength 0.15
- Genevieve Marie Boland · 1 shared paper, 2024 · strength 0.15
- Hua Ma · 1 shared paper, 2024 · strength 0.15
- Hannah Johnson Roberts · 1 shared paper, 2024 · strength 0.15
- Aparna R. Parikh · 1 shared paper, 2024 · strength 0.15
- Colin D. Weekes · 1 shared paper, 2024 · strength 0.15
- Christian T. Farrar · 1 shared paper, 2020 · strength 0.08
- Veronica Clavijo Jordan · 1 shared paper, 2020 · strength 0.08
- Theodoros P. Michelakos · 1 shared paper, 2020 · strength 0.08
- Vikram Deshpande · 1 shared paper, 2020 · strength 0.08
- Akhil Chawla · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.